Patient accuracy and confidence in self-RhD typing using a point-of-care blood typing kit

Telehealth for medication abortion has decreased many barriers to abortion care in the United States, but rhesus D (RhD) blood typing recommendations for patients beyond 84 days gestational duration can serve as a barrier for timely abortion.1–3 Additionally, self-determining RhD status may aid patients pursuing self-managed abortion, and can also reduce costs associated with travel, laboratory tests or time off work associated with traditional care at 84+ gestational days. EldonCard is a point-of-care RhD typing test.4

This was a companion study of a prior feasibility study wherein patients completed the EldonCard testing themselves and interpreted their blood type5; however, our original study’s findings were limited by the low incidence of RhD-negative patients in our study sample. This companion study sought to evaluate how well patients could interpret three pre-made sample EldonCards with both RhD-positive and RhD-negative results. Secondary objectives of this…

Read the full article ›